Relapses of clostridium difficile hard to treat

A new study suggests that healthcare professionals aren't happy with the tools they have to fight the growing problem of Clostridium difficile infections in hospitals. C. diff. is a gram-positive bacterium that can cause life-threatening conditions, especially a new hypervirulent strain known as BI/NAP1/027.

Infectious disease specialists responding to a recent survey said that they believe the industry needs new treatment regimens that provide lower relapse rates than the drugs now used, said the study, which was performed by Arlington Medical Resources and Decision Resources.

Right now, C. diff. is commonly treated with oral metronidazole and oral vancomycin, both for first episodes and relapses. However, infectious disease experts said new strains of C. diff. and the lack of second-line therapies pose significant treatment issues.

To learn more about the study:
- read this Healthcare Finance News piece

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.